


 Cite this: *RSC Adv.*, 2020, 10, 13866

# Highly efficient catalyst-free domino conjugate addition, decarboxylation and esterification/amidation of coumarin carboxylic acid/esters with pyrazolones: a green chemistry approach†

 Shanta Raj Lakshmi, Vipin Singh and L. Raju Chowhan \*

Tandem conjugate addition, decarboxylation and esterification/amidation of coumarin 3-carboxylic acid derivatives with pyrazolones have been developed. The reactions were performed with coumarin 3-carboxylic acid/esters and pyrazolone in alcohol as a solvent to afford the corresponding pyrazolyl 2-hydroxy phenylpropionate derivatives. Amines and green solvents were employed for amidation in the addition reaction. The methodology has advantages such as excellent yields, a broad substrate scope, catalyst-free, easy purification by simple filtration without any workup, mild conditions and does not require any organic solvents, ligands, base or any additives. This is a green and general synthetic protocol, which could be applicable for the synthesis of substituted pyrazolyl phenyl propionate/amide derivatives. This approach demonstrates the importance of the coumarin 3-carboxylic acid/ester core structure for Michael addition.

Received 28th January 2020

Accepted 13th March 2020

DOI: 10.1039/d0ra01906b

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

Coumarins are naturally occurring and one of the most important classes of organic molecules.<sup>1</sup> These compounds have gained considerable interest due to their wide range of biological activities such as anti-oxidants,<sup>2</sup> antiasthmatics,<sup>3</sup> anti-coagulants,<sup>4</sup> anti-inflammatories,<sup>5</sup> antivirals,<sup>6</sup> antidepressants,<sup>7</sup> antimicrobials,<sup>8</sup> antinociceptives,<sup>9</sup> and anti-tumour agents;<sup>10</sup> some naturally occurring coumarin derivatives include warfarin,<sup>11</sup> aesculetin,<sup>12</sup> and herniarin.<sup>13</sup> Furthermore, coumarins show optical properties and their wide applications in laser dyes,<sup>14</sup> fluorescent probes,<sup>15</sup> and solar cells<sup>16</sup> have been reported. On the other hand, pyrazolones are also an important class of compounds in synthetic and medicinal chemistry. These derivatives show numerous bioactivities such as edaravone is marketed as a drug for treating brain and myocardial ischemia,<sup>17</sup> and has antitumor,<sup>18</sup> anti-tubercular,<sup>19</sup> anti-inflammatory,<sup>20</sup> anti-fungal,<sup>21</sup> antibacterial,<sup>22</sup> antimycobacterial,<sup>23</sup> antifilarial<sup>24</sup> and antidepressant<sup>25</sup> activities.

The hybridization of potential molecules has been known to show improved biological activities compared to their corresponding individual lead compounds. Due to the interesting properties of coumarin and pyrazole, we were interested to

synthesise a new class of compounds, which could show better properties.<sup>26</sup> In recent years, coumarin 3-carboxylic acids are used as Michael acceptors to generate 3,4-dihydro coumarin derivatives. However, these reactions require harsh conditions, activation by a catalyst because of coumarin loses its aromaticity partially, thus limiting the reaction scope.

Recently, Xiao *et al.*<sup>27</sup> reported the synthesis of 3,4-dihydrocoumarines *via* the addition/decarboxylation of coumarin/thiocoumarin carboxylic acids with indole (Scheme 1). Franz *et al.*<sup>28</sup> disclosed the La(OTf)<sub>3</sub>-catalysed three-component reaction of coumarin 3 carboxylates for the synthesis of indolylmalonamides. Lin *et al.*<sup>29</sup> reported the  $\alpha$ -addition of  $\gamma$ -butyrolactams to coumarin derivatives, and Han *et al.*<sup>30</sup> reported the Rh-catalysed C sp<sup>2</sup>-H arylation of coumarins for the synthesis of 3,4-dihydro coumarins. To the best of our knowledge, to date, there is no direct report on the addition of pyrazolone on coumarins for the synthesis of pyrazolyl phenylpropionate derivatives.<sup>31</sup> Therefore, herein, we report a simple catalyst-free domino conjugate addition, decarboxylation and esterification/amidation of coumarins for the synthesis of pyrazolyl 2-hydroxy phenyl propionic ester/amide derivatives under green reaction conditions.


## Results and discussion

In recent times, various investigations have focused on non-traditional synthetic protocols to replace volatile harmful solvents with green solvents, such as aqueous media, ionic liquids, and medium derived from natural feedstocks or

Centre for Applied Chemistry, Central University of Gujarat, Sector 30, Gandhinagar, 382030, India. E-mail: [rchowhan@cug.ac.in](mailto:rchowhan@cug.ac.in)

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra01906b






Scheme 1 Decarboxylative additions on coumarins.

solvent-free conditions.<sup>32,43</sup> In pursuit of developing a green methodology for the synthesis of bioactive molecules,<sup>33</sup> we began our study for the synthesis of pyrazolyl phenyl propionates **3** with coumarin 3-carboxylic acid **1a** and 5-methyl-2,4-dihydro-3H-pyrazol-3-one **2a** (Scheme 2). The reaction was performed in various solvents for solvent screening at room temperature for 48 h but did not yield any product.

Then, we carried out the reaction at various temperatures, and reaction at 65 °C in water, surprisingly, afforded the pyrazolyl phenylpropionic acid **3a** in 87% yield as a white solid instead of pyrazolyl 3,4-dihydro coumarin after 18 h. The reaction at a higher temperature did not show any effect on the yield of the product. The alcohol solvents were afforded with the corresponding esters as the products. The results are summarised in Table 1. Therefore, from Table 1, it was concluded that the reaction at 65 °C in water/alcohol/Me-THF is the best-optimised reaction condition.



Scheme 2 Optimization of reaction conditions.

Table 1 Optimization of condition for the synthesis of pyrazolyl coumarin 3-carboxylates

Entry <sup>a</sup>	Solvent	Temp (°C)	Time (h)	Yield <sup>b</sup> (%)
1	H <sub>2</sub> O	r.t	48	N.R
2	CHCl <sub>3</sub>	r.t	48	N.R
3	MeOH	r.t	48	N.R
4	THF	r.t	48	N.R
5	H <sub>2</sub> O	65	18	87 <sup>c</sup>
6	H <sub>2</sub> O	100	18	87 <sup>c</sup>
7	MeOH	65	18	92 <sup>d</sup>
8	i-PrOH	65	18	96 <sup>e</sup>
9	Me-THF	65	18	92 <sup>c</sup>


<sup>a</sup> All reactions were carried out using coumarin **1a** (1 mmol) and pyrazolone **2a** (1 mmol) in the specified solvents (0.25 M). <sup>b</sup> Isolated yield. <sup>c</sup> Obtained acid derivative of **3a**. <sup>d</sup> Methyl ester of **3a** obtained. <sup>e</sup> i-propyl ester of **3a** obtained.

Under the optimised condition, the scope of the methodology was studied by varying the substitution on coumarin 3-carboxylic acid's phenyl ring such as alkyl, alkoxy and halogen group at 6<sup>th</sup> position, and we found that the reaction was clean and afforded the products **3b–e** in high yields (Table 2). Further, the reaction was performed with various methyl/ethyl carboxylates of coumarin **1** and 5-methyl-2,4-dihydro-3H-pyrazol-3-one **2a** in water afforded the same pyrazolyl phenyl propionic acids **3a–e**.

The reaction was carried out in different alcohols such as methanol, and isopropyl alcohol as solvents under the optimised conditions, and we obtained the corresponding ester derivatives **3f–i**. It is worth mentioning that edaravone is a commercially available drug molecule, which was employed in the reaction under the optimised conditions with various coumarin 3-carboxylic acid/esters which afforded the pyrazolyl phenyl propionic acid **3j–m** derivatives in good yields. It is interesting to note that irrespective of the coumarin 3-carboxylic acid/ester as a starting material the formation of the acid/ester as the product depends on the solvent used. In an aqueous reaction medium, coumarin 3-carboxylic acid and esters afforded pyrazolyl phenyl propionic acid **3a–e** as the product, and alcohol (MeOH, i-PrOH) as a solvent afforded the corresponding pyrazolyl phenyl propionic ester **3f–m** as the product. In view of the above observations, we were interested to explore the possibility of the amidation reaction as most of the drug molecules and natural products commonly possess amide functionality. Several coumarin amide derivatives are shown to be pesticidal,<sup>34</sup> anti-bacterial,<sup>35</sup> cytotoxic,<sup>36</sup> chemosensors,<sup>37</sup> and hMAO inhibitors.<sup>38</sup> In recent years, several methods were reported for the synthesis of amines from the corresponding carboxylic acids and amines catalysed by diborane,<sup>39</sup> tetramethyl orthosilicate,<sup>40</sup> aryl boronic acid,<sup>41</sup> and XtalFluor-E.<sup>42</sup>

However, these methods involve expensive catalysts, volatile solvents and anhydrous inert conditions. Therefore, to synthesis amides from coumarins *via* a catalyst-free method, a one-pot domino decarboxylative amidation reaction was



Table 2 Substrate scope for the decarboxylative addition of pyrazolones<sup>ab</sup>

<sup>a</sup> All reactions were carried out using coumarin 3-carboxylic acid/ester **1** (1 mmol) and pyrazolone **2** (1 mmol) in the specified solvents (0.25 M).

<sup>b</sup> Isolated yield.


performed in methyl THF as a green solvent using coumarin 3-carboxylic acid **1**, 5-methyl-2,4-dihydro-3H-pyrazol-3-one **2** and benzylamine **4** as the substrates. To our delight, the corresponding pyrazolyl amide product **5a** was afforded in 92% yield (Table 3). Under the optimised condition, the reaction was explored for the substrate scope. The reaction proceeded smoothly with benzylamine and methyl, bromo coumarins to afford the amide products **5b** and **5c**. We further explored the scope of the reaction with *p*-methoxy benzylamine on various coumarins. Simple, Me, OMe and halogenated coumarins performed exceptionally well to give the desired amides **5d–h** in high yields. Halo benzylamine also afforded the desired product **5i–o** in good yields. To explore the steric effect, the reaction was planned with  $\alpha$ -substituted amines. (*R*)- $\alpha$ -Methyl benzylamine employed on various coumarins afforded an approximately equal amount of inseparable diastereomeric mixture of amide derivatives **5p–t** in high yields. Coumarin 3-carboxylic acids and

esters specifically afforded exclusively same amides **5a–c** under a mild reaction condition.


We made efforts to synthesis these derivatives *via* the direct Michael addition of pyrazolone **2a** to coumarin 3-carboxylic **1a** acid to get the corresponding Michael adduct or product **3a/5a**. Therefore, the reaction performed using hydroxycinnamic acid **6** and pyrazolone **2a** in methanol refluxed for 20 h did not yield any product (Scheme 3). Similarly, the reaction with benzyl amines in Me-THF failed to give the desired products. Reaction with 3-acyl coumarin **7** and pyrazolone **2a** did not yield any product and led to the decomposition of the starting material. However, the chalcone **8** afforded Michael adduct **9**. These observations enhanced the importance of the present protocol and importance of the coumarin structure with 3-carboxylic acid/ester, which could make a better Michael acceptor in this reaction.

Based on our observations and previous reports, we propose the following mechanism for the reaction. The substrate 5-



Table 3 Substrate scope for the decarboxylative addition of pyrazolones and an amidation reaction<sup>ab</sup>

<sup>a</sup> All reactions were carried out using coumarin 3-carboxylic acid/ester **1** (1 mmol), pyrazolone **2** (1 mmol) and amine **4** (1.1 mmol) in Me-THF (0.25 M). <sup>b</sup> Isolated yield.



Scheme 3 Direct Michael addition with other substrates.

methyl-2,4-dihydro-3H-pyrazol-3-one **2** will be in equilibrium with its enol form **10** and undergoes Michael addition in the first step to afford the Michael adduct **11** (Fig. 1). The adduct **11** undergoes decarboxylation to afford intermediate **12**, which on isomerization forms intermediate **13**. The addition of solvent ROH will form intermediate **14**, which subsequently undergoes the ring-opening to afford the product **3**.<sup>29</sup> The mass spectroscopic data was recorded after 5, 10, 15, 20 min intervals of the reaction. The intermediate **11** and **13** were observed in mass spectrum *m/z* at 289 and 245, respectively, within 5 min of the reaction and the product **3** appeared after 15 min. These observations support the proposed mechanism.






Fig. 1 Plausible reaction mechanism.

## Conclusions

In conclusion, we have developed a simple green methodology for the synthesis of pyrazolyl phenyl propionic acid *via* tandem Michael addition, decarboxylation and esterification/amidation in one pot operation under mild conditions without the use of any toxic solvents or metals. The methodology has a broad substrate scope with good yields. In particular, acids were obtained in aqueous reactions and corresponding esters in alcohol as solvents. A series of amides were synthesised by employing this catalyst-free method. The green methodology could be useful for the development of bioactive molecules or lead compounds in a one-pot operation.

## Experimental

In a 5 mL round bottom flask containing a solution of coumarin 3-carboxylic acid **1** (1 mmol) in 4 mL of solvent (water/MeOH/i-PrOH), 5-methyl-2,4-dihydro-3H-pyrazol-3-one **2a** (1 mmol) was added. The reflux condenser was fixed, and the reaction mixture was stirred for 18 h at 65 °C (the reaction mixture becomes homogeneous while the reaction is in progress). The progress of the reaction was monitored by TLC. After the completion of the reaction, the solid product **3a** was filtered using a sintered glass funnel and washed with water (2 × 10 mL) and MeOH (2 × 10 mL). The solid was collected and dried in a vacuum. The obtained product was pure and did not require any further purification.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

SRL thanks UGC-India for Non-NET fellowship, VS thanks UGC-India for RGNF, Authors thanks to CUG-India for financial and infrastructural support.

## Notes and references

- 1 F. G. Medina, J. G. Marrero, M. Macías-Alonso, M. C. González, I. Córdova-Guerrero, A. G. T. García and S. Osegueda-Robles, *Nat. Prod. Rep.*, 2015, **32**, 1472.
- 2 I. Kostova, S. Bhatia, P. Grigorov, S. Balkansky, V. S. Parmar, A. K. Prasad and L. Saso, *Curr. Med. Chem.*, 2011, **18**, 3929.
- 3 A. Sánchez-Recillas, G. Navarrete-Vázquez, S. Hidalgo-Figueroa, M. Y. Rios, M. Ibarra-Barajas and S. Estrada-Soto, *Eur. J. Med. Chem.*, 2014, **77**, 400.
- 4 X. M. Peng, G. L. Damu and C. Zhou, *Curr. Pharm. Des.*, 2013, **19**, 3884.
- 5 Y. Bansal, P. Sethi and G. Bansal, *Med. Chem. Res.*, 2013, **22**, 3049.
- 6 (a) J. R. Hwu, S. Y. Lin, S. C. Tsay, E. De Clercq, P. Leyssen and J. Neyts, *J. Med. Chem.*, 2011, **54**, 2114; (b) E. B. B. Ong, N. Watanabe, A. Saito, Y. Futamura, K. H. A. El Galil, A. Koito, N. Najimudin and H. Osada, *J. Biol. Chem.*, 2011, **286**, 14049.
- 7 K. V. Sashidhara, A. Kumar, M. Chatterjee, K. B. Rao, S. Singh, A. K. Verma and G. Palit, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 1937.
- 8 (a) D. A. Ostrov, J. A. Hernandez-Prada, P. E. Corsino, K. A. Finton, N. Le and T. C. Rowe, *Antimicrob. Agents Chemother.*, 2007, **51**, 3688; (b) F. Chimenti, B. Bizzarri, A. Bolasco, D. Secci, P. Chimenti, A. Granese, S. Carradori, D. Rivanera, A. Zicari, M. M. Scaltrito and F. Sisto, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 4922.
- 9 T. A. De Almeida Barros, L. A. R. De Freitas, J. M. B. Filho, X. P. Nunes, A. M. Giulietti, G. E. De Souza, R. R. Dos Santos, M. B. P. Soares and C. F. Villarreal, *J. Pharm. Pharmacol.*, 2010, **62**, 205.
- 10 (a) A. Lacy and R. O'Kennedy, *Curr. Pharm. Des.*, 2004, **10**, 3797; (b) M. A. Musa, J. S. Cooperwood and M. O. F. Khan, *Curr. Med. Chem.*, 2008, **15**, 2664; (c) L. R. Zacharski, W. G. Henderson, F. R. Rickles, W. B. Forman, C. J. Cornell Jr, R. J. Forcier, R. L. Edwards, E. Headley, S. H. Kim, J. F. O'Donnell, R. O'Dell, K. Tornyo and H. C. Kwaan, *Cancer*, 1984, **53**, 2046.
- 11 F. Borges, F. Roleira, N. Milhazes, L. Santana and E. Uriarte, *Curr. Med. Chem.*, 2005, **12**, 887.
- 12 A. Lacy and R. O'Kennedy, *Curr. Pharm. Des.*, 2004, **10**, 3797.
- 13 (a) A. Ahmad and L. N. Misra, *Int. J. Pharmacogn.*, 1997, **35**, 121; (b) O. R. Gottlieb, K. Herrmann, R. D. H. Murray, G. Ohloff and G. Pattenden, *Progress in the Chemistry of Organic Natural Products*, New York, Springer-Verlag, 1978.
- 14 L. L. Skowronski, O. Krupka, V. Smokal, A. Grabowski, M. Naparty and B. Derkowska-Zielinska, *Opt. Mater.*, 2015, **47**, 18.



- 15 (a) M. Tasiar, D. Kim, S. Singha, M. Krzeszewski, K. Han Ahn and D. T. Gryko, *J. Mater. Chem. C*, 2015, **3**, 1421; (b) G. Jones II and M. A. Rahman, *J. Phys. Chem.*, 1994, **98**, 13028.
- 16 K. Hara, T. Sato, R. Katoh, A. Furube, Y. Ohga, A. Shinpo, S. Suga, K. Sayama, H. Sugihara and H. Arakawa, *J. Phys. Chem. B*, 2003, **107**(2), 597.
- 17 (a) T. Watanabe, S. Yuki, M. Egawa and H. Nishi, *J. Pharmacol. Exp. Ther.*, 1994, **268**, 1597; (b) H. Kawai, H. Nakai, M. Suga, S. Yuki, T. Watanabe and K. I. Saito, *J. Pharmacol. Exp. Ther.*, 1997, **281**, 921; (c) T. W. Wu, L. H. Zeng, J. Wu and K. P. Fung, *Life Sci.*, 2002, **71**, 2249.
- 18 F. A. Pasha, M. Muddassar, M. M. Neaz and S. J. Cho, *J. Mol. Graphics Modell.*, 2009, **28**, 54–61.
- 19 P. Gunasekaran, S. Perumal, P. Yogeewari and D. Sriram, *Eur. J. Med. Chem.*, 2011, **46**, 4530.
- 20 E. A. M. Badawey and I. M. El-Ashmawey, *Eur. J. Med. Chem.*, 1998, **33**, 349.
- 21 M. A. Al-Haiza, S. A. El-Assiery and G. H. Sayed, *Acta Pharm.*, 2001, **51**, 251.
- 22 F. Moreau, N. Desroy, J. M. Genevard, V. Vongsouthi, V. Gerusz, G. Le Frallic, C. Oliveira, S. Floquet, A. Denis, S. Escaich, K. Wolf, M. Busemann and A. Aschenbsenner, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 4022.
- 23 D. Castagnolo, F. Manetti, M. Radi, B. Bechi, M. Pagano, A. De Logu, R. Meleddu, M. Saddi and M. Botta, *Bioorg. Med. Chem.*, 2009, **17**, 5716.
- 24 P. M. S. Chauhan, S. Singh and R. K. Chatterjee, *Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.*, 1993, **32**, 858.
- 25 D. M. Bailey, P. E. Hansen, A. G. Hlavac, E. R. Baizman, J. Pearl, A. F. Defelice and M. E. Feigenson, *J. Med. Chem.*, 1985, **28**, 256.
- 26 P. P. Ghosh, G. Pal, S. Paul and A. R. Das, *Green Chem.*, 2012, **14**, 2691.
- 27 Z. Shao, L. Xu, L. Wang, H. Wei and J. Xiao, *Org. Biomol. Chem.*, 2014, **12**, 2185.
- 28 J. J. Jennings, C. P. Bhatt and A. K. Franz, *J. Org. Chem.*, 2016, **81**, 6211.
- 29 S. Yang, G. M. Reddy, M. Liu, T. Wang, J. Yu and W. Lin, *J. Org. Chem.*, 2017, **82**, 781.
- 30 F. Han, S. Xun, L. Jia, Y. Zhang, L. Zou and X. Hu, *Org. Lett.*, 2019, **21**, 5907.
- 31 M. Bakthadoss, D. Kannana and R. Selvakumar, *Chem. Commun.*, 2013, **49**, 10947.
- 32 (a) K. D. Dwivedi, B. Bora and L. R. Chowhan, *Front. Chem.*, 2020, **7**, 944; (b) K. D. Dwivedi, M. S. Reddy, N. S. Kumar and L. R. Chowhan, *ChemistrySelect*, 2019, **4**, 8602; (c) L. R. Chowhan, M. S. Reddy and N. S. Kumar, *J. Chem. Sci.*, 2017, **129**, 1205; (d) C. J. Clarke, W. Tu, O. Levers, A. BröhlJason and P. Hallett, *Chem. Rev.*, 2018, **118**, 747.
- 33 (a) P. Ramesh, M. S. Reddy, N. S. Kumar, B. Rathod, R. S. Prakasham and L. R. Chowhan, *ChemistrySelect*, 2018, **3**, 9096; (b) M. S. Reddy, L. R. Chowhan, N. S. Kumar, P. Ramesh and S. B. Mukkamala, *Tetrahedron Lett.*, 2018, **59**, 1366; (c) L. R. Chowhan and S. Raghavan, *Tetrahedron Lett.*, 2019, **60**, 151132; (d) V. Singh, S. R. Lakshmi and L. R. Chowhan, *ChemistrySelect*, 2019, **4**, 13601.
- 34 Y. Wei, K. Miao and S. Hao, *Molecules*, 2018, **23**, 122.
- 35 M. Chen, D. Lu and X. Zhang, *Chem. Pap.*, 2017, **71**, 1579.
- 36 T. Nasr, S. Bondock, H. M. Rashed, W. Fayad, M. Youns and T. M. Sakr, *Eur. J. Med. Chem.*, 2018, **151**, 723.
- 37 (a) Q. Wu, Z. Liu, D. Cao, R. Guan, K. Wang, Y. Shan, Y. Xu and L. Ma, *Mater. Chem. Phys.*, 2015, **161**, 43; (b) Z. Wang, Q. Wu, J. Li, S. Qiu, D. Cao, Y. Xu, Z. Liu, X. Yu and Y. Sun, *Spectrochim. Acta, Part A*, 2017, **183**, 1; (c) S. Sumiya, Y. Shiraishi and T. Hirai, *J. Phys. Chem. A*, 2013, **117**, 1474.
- 38 (a) F. Chimenti, D. Secci, A. Bolasco, P. Chimenti, B. Bizzarri, A. Granese, S. Carradori, M. Yáñez, F. Orallo and F. Ortuso, *J. Med. Chem.*, 2009, **52**, 1935; (b) C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D. E. Edmondson and A. Mattevi, *J. Med. Chem.*, 2007, **50**, 5848; (c) A. Stefanachi, F. Leonetti, L. Pisani, M. Catto and A. Carotti, *Molecules*, 2018, **23**, 250.
- 39 D. N. Sawant, D. B. Bagal, S. Ogawa, K. Selvam and S. Saito, *Org. Lett.*, 2018, **20**(15), 4397.
- 40 D. C. Braddock, P. D. Lickiss, B. C. Rowley, D. Pugh, T. Purnomo, G. Santhakumar and S. J. Fussell, *Org. Lett.*, 2018, **20**, 950.
- 41 (a) T. M. E. Dine, W. Erb, Y. Berhault, J. Rouden and J. Blanchet, *J. Org. Chem.*, 2015, **80**, 4532; (b) N. Gernigon, R. M. Al-Zoubi and D. G. Hall, *J. Org. Chem.*, 2012, **77**, 8386.
- 42 A. Orliac, D. G. Pardo, A. Bombrun and J. Cossy, *Org. Lett.*, 2013, **15**, 902.
- 43 M. S. Reddy, N. S. Kumar and L. R. Chowhan, *RSC Adv.*, 2018, **8**, 35587–35593.

